Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a traditional chinese herbal remedy stop stroke patients from getting worse?

NCT ID NCT06857487

Disease control Sponsor: Dongzhimen Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a traditional Chinese herbal formula called Qingre Huatan can prevent early neurological deterioration in people who have had an acute ischemic stroke within the last 48 hours. The trial will involve 72 participants, who will receive either the herbal granules or a placebo twice daily for 10 days, alongside standard stroke care. The main goal is to see if the formula reduces the risk of worsening symptoms within the first week.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Qingre Huatan formula (herbal granules)
What this could lead to
If it works, this could offer a new way to prevent early neurological decline after a stroke, potentially reducing long-term disability.
What could go wrong
This is a small, early-phase pilot trial with only 72 participants, so results may not be conclusive. The herbal formula may not outperform placebo, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Inpatients diagnosed with acute ischemic stroke. Inpatients diagnosed of acute ischemic stroke. 2. Meet the criteria of TCM phlegm-heat syndrome 3. Patients at high-risk of END : Magnetic resonance imaging (MRI) reveals new ischemic lesions, with DWI-ASPECTS score ≤ 7, or presence of at least two risk factors of END. 4. Acute ischemic stroke within 48 hours after onset. 5. Aged 18-80 years, male or female. 6. The patient or representative has signed informed consent. Exclusion Criteria: 1. Received or planned thrombolysis or endovascular therapy after onset. 2. Suspected secondary stroke caused by brain tumor, brain trauma, hemopathy, etc. 3. Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scare score ≥2 ) 4. Diseases that cause motor dysfunction, including osteoarthritis, etc. 5. Known severe liver or kidney dysfunction (alanine aminotransferase or aspartate transaminase \> 2 times the upper limit of normal value, serum creatinine \> 1.5 times the upper limit of normal value) 6. Known severe aphasia or mental illness affecting clinical information collection and evaluation. 7. Pregnancy, potential pregnancy or breastfeeding. 8. Currently participating in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dongzhimen Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100700, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.